Related Experiment Video
Updated: Apr 5, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
1.3K
Association between plasma fluorescent oxidation products and erectile dysfunction: A prospective study.
Shuman Yang1, Edward Giovannucci2,3, Bruce Bracken4
1Division of Epidemiology and Biostatistics, Department of Environmental Health, University of Cincinnati Medical Center, Kettering Complex, 3223 Eden Ave, Cincinnati, OH, USA, 45267-0056. ysm992511@sina.com.
BMC Urology
|August 15, 2015
Summary
Oxidative stress biomarkers, plasma fluorescent oxidation products (FlOPs), were not associated with erectile dysfunction (ED) risk in a large prospective study. These findings suggest oxidative stress may not be an independent risk factor for ED.
Area of Science:
- Urology
- Oxidative Stress Research
- Epidemiology
Background:
- Epidemiological studies on oxidative stress and erectile dysfunction (ED) are limited and inconclusive.
- Previous research often used cross-sectional designs and small sample sizes, hindering definitive conclusions.
Purpose of the Study:
- To investigate the association between biomarkers of oxidative stress and ED.
- To examine this relationship in a prospective setting with a large sample size.
Main Methods:
- A prospective study was conducted on 917 men aged 47-80.
- Plasma fluorescent oxidation products (FlOPs) were measured as a global biomarker for oxidative stress.
- Three excitation/emission wavelengths (FlOP_360, FlOP_320, FlOP_400) were analyzed.
Main Results:
- Approximately 35% of participants developed ED during the follow-up period.
- No independent association was found between FlOP_360, FlOP_320, or FlOP_400 and the risk of ED in multivariable adjusted models.
- Further analysis in fasting samples or controls did not significantly alter these results.
Conclusions:
- Plasma FlOPs were not associated with an increased risk of ED.
- The findings suggest that oxidative stress may not be an independent risk factor for ED.
Related Concept Videos
01:17Male Sexual Response: Erection & Ejaculation
27.8K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
27.8K
01:20Disorders of the Male Reproductive System
5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
743
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
743
01:28Nitric Oxide Signaling Pathway
6.8K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.8K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
01:26Coronary Artery Disease II: Pathophysiology
994
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
994